YIH
STLN

Y-Intercept (HK)’s Starling Oncology STLN Stock Holding History

Y-Intercept (HK)’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-138,899
Closed -$76.4K – 1601
2023
Q2 		$76.4K Buy
+138,899
New +$73.5K 0.01% 1148

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Y-Intercept (HK)'s STLN Position: Q3 2023 in Review

Y-Intercept (HK) sold out of Starling Oncology (STLN) in Q3 2023, closing a stake of 138,899 shares — an estimated $76.4K sold.

Y-Intercept (HK) first reported a position in STLN in Q2 2023 and held it in 1 quarter. The position peaked at $76.4K in Q2 2023. 36 funds tracked by Wall St. Rank hold STLN as of Q3 2023.

  • Y-Intercept (HK) reported no remaining Starling Oncology position as of Q3 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 138,899 Starling Oncology shares in Q3 2023, an estimated $76.4K.
  • Y-Intercept (HK) first reported a position in Starling Oncology in Q2 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s Starling Oncology position peaked at $76.4K in Q2 2023.
  • 36 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2023.

Based on Y-Intercept (HK)'s 13F filing for Q3 2023, filed 14 Nov 2023.